Android app on Google Play

Onyx (ONXX) Delays NDA for Carfilzomib Due to Recent CMC Meeting

October 7, 2010 4:59 PM EDT Send to a Friend
Onyx (Nasdaq: ONXX) delaying its NDA for carfilzomib based on a recent CMC meeting. The FDA requested added CMC information.

Onyx expects to file an NDA for accelerated approval as early as mid-2011.

The company has said the clinical profile of carfilzomib has not changed.




You May Also Be Interested In


Related Categories

Corporate News, FDA, Hot List

Add Your Comment